ADMA Biologics (NASDAQ:ADMA) Downgraded to Strong Sell Rating by Zacks Research

Zacks Research downgraded shares of ADMA Biologics (NASDAQ:ADMA) from a hold rating to a strong sell rating in a report released on Tuesday morning,Zacks.com reports.

Several other research analysts have also recently commented on the company. Mizuho lowered their target price on ADMA Biologics from $20.00 to $17.00 and set an “outperform” rating for the company in a research note on Wednesday, July 15th. Weiss Ratings restated a “hold (c)” rating on shares of ADMA Biologics in a research note on Thursday, June 18th. Canaccord Genuity Group decreased their price target on shares of ADMA Biologics from $21.00 to $18.00 and set a “buy” rating for the company in a research note on Thursday, May 7th. Wall Street Zen cut shares of ADMA Biologics from a “buy” rating to a “hold” rating in a report on Monday, May 4th. Finally, Raymond James Financial started coverage on shares of ADMA Biologics in a report on Wednesday, June 10th. They issued an “outperform” rating and a $21.00 price objective on the stock. Three investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, ADMA Biologics presently has a consensus rating of “Hold” and a consensus target price of $18.67.

ADMA Biologics Trading Up 3.9%

NASDAQ ADMA opened at $9.26 on Tuesday. The company has a debt-to-equity ratio of 0.51, a quick ratio of 3.93 and a current ratio of 6.95. The firm has a market cap of $2.15 billion, a price-to-earnings ratio of 13.62 and a beta of 0.74. The firm has a 50 day simple moving average of $8.55 and a 200-day simple moving average of $11.37. ADMA Biologics has a one year low of $7.21 and a one year high of $20.46.

ADMA Biologics (NASDAQ:ADMA) last released its earnings results on Wednesday, August 5th. The biotechnology company reported $0.16 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.16. The company had revenue of $124.39 million for the quarter, compared to analyst estimates of $125.34 million. ADMA Biologics had a net margin of 32.43% and a return on equity of 39.98%. The firm’s quarterly revenue was up 2.0% on a year-over-year basis. During the same period in the prior year, the business earned $0.14 EPS. Equities research analysts anticipate that ADMA Biologics will post 0.8 EPS for the current fiscal year.

Insider Activity

In other news, Director Jerrold B. Grossman purchased 12,500 shares of the stock in a transaction dated Monday, May 11th. The stock was acquired at an average cost of $8.01 per share, for a total transaction of $100,125.00. Following the completion of the acquisition, the director directly owned 513,884 shares in the company, valued at $4,116,210.84. This represents a 2.49% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 3.90% of the stock is owned by company insiders.

Institutional Trading of ADMA Biologics

A number of institutional investors have recently modified their holdings of ADMA. Summit Securities Group LLC acquired a new position in shares of ADMA Biologics during the fourth quarter worth about $29,000. Optima Capital LLC purchased a new stake in ADMA Biologics during the 4th quarter worth approximately $36,000. iSAM Funds UK Ltd bought a new stake in shares of ADMA Biologics in the third quarter worth $34,000. Morse Asset Management Inc bought a new stake in shares of ADMA Biologics in the 4th quarter worth about $44,000. Finally, Nkcfo LLC bought a new stake in ADMA Biologics in the fourth quarter valued at about $47,000. Hedge funds and other institutional investors own 75.68% of the company’s stock.

Key Headlines Impacting ADMA Biologics

Here are the key news stories impacting ADMA Biologics this week:

• Positive Sentiment: ADMA reported second-quarter revenue of $124.4 million, up 2% year over year, while GAAP net income rose 11% to $37.8 million. Adjusted EBITDA increased 22% to $61.8 million, supporting the company’s profitability profile. ADMA Biologics Reports Second Quarter 2026 Financial Results and Provides Business Update
• Positive Sentiment: Quarterly EPS met the $0.16 analyst consensus, and ASCENIV revenue climbed 24% to $102.9 million. Management also said BIVIGAM demand and revenue stabilized sequentially, indicating improving utilization trends. ADMA Biologics Q2 Earnings Snapshot
• Positive Sentiment: The company reiterated 2026 revenue guidance of $530 million to $560 million, broadly consistent with the $534.9 million consensus estimate, and is targeting more than $200 million in share repurchases. Buybacks could provide demand for the stock and increase per-share value if executed. ADMA Reiterates 2026 Guidance and Targets Share Repurchases
• Neutral Sentiment: Management highlighted new real-world evidence on ASCENIV’s patient outcomes and healthcare-resource utilization, potentially supporting longer-term demand, although the evidence remains an upcoming catalyst rather than a reported financial result.
• Negative Sentiment: Multiple law firms are promoting a securities-fraud class action covering investors who purchased ADMA securities from August 9, 2024, through March 25, 2026. The complaints allege misleading statements involving revenue, financial condition, inventory distribution and business practices. Lead-plaintiff notices cite an August 10 deadline. The allegations have not been proven, but the litigation creates legal costs, reputational risk and potential financial exposure. ADMA Securities Fraud Lawsuit Notice

About ADMA Biologics

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.